An immunoenzymatic serum fingerprinting method was developed to establish a serum sample fingerprint based on IgG titres obtained with three different antigens.
Introduction
Biobanks are infrastructures, specialized in the acquisition, processing, validation, conservation, management and distribution of renewable (cells, nucleic acids) and non-renewable (serum, plasma, solid tissues, proteins) biospecimens for research purposes. Serum and plasma samples, stored in biobanks, are often used in simple or multiplex serological or high-throughput proteomic comparative case-control studies. The scientific validity of such studies depends on a number of pre-analytical, analytical and post-analytical parameters. Indeed, preanalytical variations can introduce significant bias in molecular profiles for diseases (18) .
The importance of the traceability of serum samples in biobanks is now recognized (9). However, the fact that two serum samples may originate from the same whole blood specimen, leading to potential errors in the identification/differentiation of such samples, is less commonly acknowledged. It is important that samples that are considered to be different (or coming from different donors) are indeed different and are not aliquots of the same original biospecimen, which have been inadvertently mis-labelled. Such errors in labeling may take place during sample collection, processing or aliquoting. The statistical validity of research results based on the use of mis-labelled samples, supposedly derived from different patients, but in reality derived from the same primary biospecimen, may then be severely comprised: the impact of this being particularly marked in studies based on relatively small numbers of cases and controls. A serum fingerprinting tool determining whether two serum samples are derived from different or from the same original whole blood specimens may be useful as a quality control tool. Mass spectrometry methods can be used to establish individual apolipoprotein CI, CII and CIII profiles, but these methods are not 4 widely available (19) . We aimed to develop a reliable, yet widely applicable and easyto-implement method.
We established a serological fingerprint on the basis of the titres of polyclonal IgG antibodies specific for three different antigens. Widely distributed and persistent serological markers were needed for high resolution and specificity. These three antigens were selected for their immunogenicity and capacity to induce long-lasting humoral immunity. We selected synthetic peptides from the EBNA-1 protein of Epstein-Barr virus (EBV), the B. pertussis toxin (PT) and the Outer Membrane Gln-Pro-Val-Glu-Gln-Lys-Ser. This fragment was found to have a hydrophobicity index of -2.5 and was thus considered a potential immunodominant epitope (17) .
The method is based on the principle that, for at least one of the three serological markers (pepPT, pepOMP2 and pepEBNA1), the difference in IgG levels between two different samples will be significantly larger than the intra-assay Coefficient of Variation (CV%) for each marker. By contrast, overlapping confidence intervals for the IgG levels of all three markers suggest that the two samples have been derived from the same blood specimen, i.e. from the same donor at a given time.
Materials and Methods

Triplex peptide fingerprinting ELISA
The three peptides pepEBNA1, pepPT and pepOMP2, coupled to an N-terminal biotin molecule through a Gly-Gly bridge, were synthesized by Neosystem (Strasbourg, France). The purity of each peptide preparation was checked by mass spectrometry. Each peptide was diluted to 2µg/ml in 0.1M carbonate/bicarbonate buffer pH 9.6 4% NaCl 0.1% Tween20 and added to streptavidin-precoated NUNC 6 microplates for one hour at 37°C. Microplates were dried and used on the same day.
Aliquots of sera, diluted 1:40 in PBS containing 0.1% Tween and 4% NaCl were added to the wells of microplates coated with pepPT and pep OMP2. Aliquots of sera, diluted 1:400 in PBS containing 0.1% Tween and 4% NaCl, were added to microplates coated with pepEBNA1. All plates were incubated at 37°C for 60 min.
Plates were then washed three times with PBS-Tween 20 and incubated with a 
Validation of serum fingerprinting method precision and specificity
To validate the precision of the method, three different serum samples from the Picardie Biobank were used as reference samples. They were tested at different dilutions against pepEBNA1, pepPT and pepOMP2 to determine the working dilutions that give "low", "intermediate" To validate the specificity of the method, we used 91 serum samples from the Picardie Biobank which were known to be from different patients. These samples were tested against pepEBNA1, pepPT and pepOMP2 in triplicate.
Study population
Serum samples were collected from 144 female patients who had been included in a previous case-control study ( trachomatis, anti-Chsp10 and anti-Chsp60 antibody titer values had been obtained by ELISA, to determine, using the fingerprinting method, whether these samples differed. Each serum sample was tested in triplicate for each of the three serological markers and the mean OD 405 value was calculated for each sample and for each marker.
Results
Peptide ELISA validation
To validate our method, we determined the working dilutions that gave "low", "intermediate" and "high" OD 405 values using reference serum samples against each of the three peptide antigens ( Table 1) .
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The combined uncertainty of measurement for each of the three serological markers and at each of the three different OD 405 levels for each marker (low, intermediate and high OD 405 values) was established using the CLSI method (6) ( Table 2) . Combined uncertainty of the mean of triplicate determinations included the day-to-day variation, inter-batch variation, the spectrophotometer and the spectrophotometer calibrator uncertainties. We applied a coverage factor of kp = 1.96, producing a 95%
confidence interval and assuming a normal distribution (11).
Method specificity was defined as the risk of falsely concluding that two samples are identical, when in reality they are different. The number of different possible binary combinations was (91 2 -91)/2 = 4095, of which only 22 gave erroneous results, falsely identifying serum samples as identical. Therefore, the discriminatory power and specificity of the fingerprinting method was 99.5% (22/4095).
Application of the serum fingerprinting method
Among 30 highly "suspicious" serum samples tested with the serum fingerprinting method, the following serum ID# were found to be identical: #042, #043, #047, and #049, corresponding to the "parent" blood specimen #042; #102, #103, #106, #108, #109, #110, #117, #118, #119, and #120, corresponding to the "parent" blood specimen #102; #112, #114, #115, and #126, corresponding to the "parent" blood specimen #112. Therefore, 18 of the 144 serum samples (12.5%) on which the original research study was based, did not correspond to distinct research subjects. (Figure 1) . The majority (92.8%) of combinations considered to be different serum samples had a confidence level of 95% (2 SD), with only 7.2% having a more ambiguous confidence level of 71% (1 SD) ( Table 3) .
We further examined these 29 ambiguous serum samples; the majority of these samples were shown to be identical by deductive reasoning using binary relations between serum samples (if a = b and b = c then a = c). 
Discussion
We tested, at a specified level of confidence, whether two serum samples, supposedly different, were really different or if they may have been inadvertently mislabeled. The biobank holds records of samples from x different individuals; however, in reality blood was collected from less than x individuals and serum from one individual was aliquoted in tubes corresponding to more than one ID#. This presents a challenge in biobanking that is existent but is rarely acknowledged. Such an anomaly may completely invalidate the statistical significance and interpretation of research results. We demonstrate a method to overcome this challenge by analysing human serum samples for the presence of specific antibodies specific for the three antigens pepPT, pepOMP2 and pepEBNA1 and comparing the corresponding serological fingerprints.
We increased the resolution of the serum fingerprinting method by selecting antigens that induce the production of long-lasting infectious or vaccine antibodies. We thus used three synthetic peptides, each from an antigen inducing humoral immunity, last for a period of at least ten years after infection or vaccination. These three antigens were sufficient to develop a serum fingerprinting method with 99.5% specificity.
The method described provides a qualitative assessment of the identity of two serum samples. This qualitative method does not depend on absolute IgG antibody titers but is based on comparisons between the relative OD 405 values for three serological markers. Since the method is not designed to provide quantitative data, it cannot be validated in terms of accuracy, linearity and sensitivity. We validate the precision of the method by determining intra-and inter-assay reproducibility. Assigning a "positive" result to two identical samples, the "diagnostic" specificity of the method is equivalent to the risk of obtaining a false conclusion that two samples are identical when these samples are, in reality, different.
When using this fingerprinting method for the quality control of a panel of supposedly different serum samples, care should be taken to ensure that the samples compared have been maintained under the same storage conditions (time, temperature, storage container type) and that no differential evaporation has occurred. It has previously been shown that IgG antibodies are extremely stable during storage at -80°C and when exposed to multiple freeze-thaw cycles (4). We would therefore expect the fingerprinting method described herein to be robust despite these preanalytical conditions. Serum fingerprinting does not allow discrimination between individual donors of serum samples as the same donor may have different IgG titres against a specific antigen over time. The method allows discrimination either between individual donors from whom samples were collected at a given time or between primary blood specimens.
The method described here offers a novel, easy-to-use and specific tool for quality control and quality assurance, overcoming a rarely acknowledged anomaly in biobanks (22). 
